Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹946.75up ₹22.95 (2.48%)BSE ₹946.65
Share price at the NSE close on 2 Nov 2026. Previous close ₹923.80.
2 Nov: open ₹925.00, high ₹949.90, low ₹919.00
52-week range of traded prices to 2 Nov 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,080 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.83
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 36.66
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.13
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,48,07658.1% delivered
Jubilant Pharmova share news and announcements
1,153 announcements, routine notices left out, newest first. Page 17 of 24.
May 2014
28 May · Dividend
Dividend, if approved, by the Members at the Annual General Meeting, will be paid/despatched on or before October 01, 2014.26 May · Updates
26 May · Dividend
Board of Directors of the Company at its meeting held on May 26, 2014 has recommended a dividend of Rs. 3 per equity shares of Rs. 1 fully paid up amounting to Rs. 5590 lacs, subject to approval in the Annual General Meeting.16 May · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2014; (2) Recommendation of Dividend for the Year ended March 31, 2014. Further as per the Company's insider Trading Code, the trading window for dealing in the securities of the Company would remain closed for all Directors/Officers/ Designated Employees of the Company from May 19, 2014 to May 27, 2014 (both days inclusive).
Apr 2014
Mar 2014
Feb 2014
6 Feb · Business
6 Feb · Legal
Exchange had sought clarification from Jubilant Life Sciences Limited with respect to a news item captioned "Jubilant May Sell Chemical Business to Reduce Debt". The Company has clarified that the news is "Incorrect, speculative and baseless. The management has also denied this and the Management response is carried in the same article which is quoted hereunder: 'Jubilant, however, termed the information speculative . The management does not comment on any such speculative and baseless statements, the group said in an emailed response to a query on the development.'"
Jan 2014
Dec 2013
Nov 2013
Oct 2013
21 Oct · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2013
Sep 2013
3 Sep · Management
Mrs. Sudha Pillai has been appointed as Additional Director of the Company with effect from September 03, 2013. She will be an independent director.
Aug 2013
27 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2013
24 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2013.
Jun 2013
17 Jun · Management
Mr. S. Sridhar has been appointed as Additional Director of the Company with effect from June 15, 2013.
May 2013
29 May · Board meeting
8 May · Board meeting
Board of Directors of the Company in its meeting held May 07, 2013 inter alia, accorded its approval to constitute a committee to explore options and opportunities to raise debt for the Company, including by way of issue of foreign currency bonds and /or non-convertible debentures, or by any one or more or a combination of the above or otherwise, to be denominated in Indian rupees or foreign currency, as the case may be, to various eligible investors in or outside India, whether by way of a public offering or by way of a private placement, in the best interests of the Company and all its stakeholders, up to an amount not exceeding US $ 250 million for prepayment of the existing debt and other general corporate purposes without increasing the overall net debt levels of the Company.8 May · Disclosure
Compensation Committee of the Board of Directors in its meeting held on May 07, 2013, inter alia, has granted 12,187 (Twelve Thousands One Hundred and Eighty Seven) Options to eligible employees of the Company, in accordance with JLL Employees Stock Option Plan, 2011. Each option shall entitle the holder to acquire 1 equity share of Re. 1 of the Company at a price of Rs. 176.00 (Rupees One Hundred and Seventy Six only) per share. Since Jubilant Employees Welfare Trust is holding sufficient number of equity shares of the Company, it is envisaged to transfer the Shares from the Trust to beneficiaries upon exercise. As such, there would be no fresh issue of Shares by the Company and hence no dilution.